Scaling Up Gene Therapy Manufacturing: Strategies to Overcome Capacity Challenges
As vector-delivered advanced therapies inch towards commercialization, a significant bottleneck has emerged: experienced manufacturing capacity.
CBM’s viral vector capabilities efficiently and consistently delivers high yields in AAV, Lentivirus, HSV and Adenovirus vectors, accelerating the development of new therapies.
CBM has one of cell therapy’s most experienced teams and the largest single site facility in the industry. There is no greater centralization of expertise.
Our team brings a wealth of experience from biopharma and advanced therapy CDMOs, ensuring that there is no safer place for your product.